Income Tax Expense (Benefit) in USD of Synchrony Financial from 2012 to Q3 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
Summary
Synchrony Financial quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2012 to Q3 2025.
  • Synchrony Financial Income Tax Expense (Benefit) for the quarter ending September 30, 2025 was $352M, a 47.3% increase year-over-year.
  • Synchrony Financial Income Tax Expense (Benefit) for the twelve months ending September 30, 2025 was $1.07B, a 11.8% increase year-over-year.
  • Synchrony Financial annual Income Tax Expense (Benefit) for 2024 was $1.05B, a 58.3% increase from 2023.
  • Synchrony Financial annual Income Tax Expense (Benefit) for 2023 was $666M, a 29.6% decline from 2022.
  • Synchrony Financial annual Income Tax Expense (Benefit) for 2022 was $946M, a 26.2% decline from 2021.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Quarterly (USD)
Income Tax Expense (Benefit), YoY Quarterly Growth (%)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)

Synchrony Financial Quarterly Income Tax Expense (Benefit) (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q3 2025 $1.07B $352M +$113M +47.3% Jul 1, 2025 Sep 30, 2025 10-Q 2025-10-22
Q2 2025 $954M $289M +$88M +43.8% Apr 1, 2025 Jun 30, 2025 10-Q 2025-07-23
Q1 2025 $866M $227M -$188M -45.3% Jan 1, 2025 Mar 31, 2025 10-Q 2025-04-24
Q4 2024 $1.05B $199M +$100M +101% Oct 1, 2024 Dec 31, 2024 10-K 2025-02-07
Q3 2024 $954M $239M +$34M +16.6% Jul 1, 2024 Sep 30, 2024 10-Q 2025-10-22
Q2 2024 $920M $201M +$28M +16.2% Apr 1, 2024 Jun 30, 2024 10-Q 2025-07-23
Q1 2024 $892M $415M +$226M +120% Jan 1, 2024 Mar 31, 2024 10-Q 2025-04-24
Q4 2023 $666M $99M -$65M -39.6% Oct 1, 2023 Dec 31, 2023 10-K 2025-02-07
Q3 2023 $731M $205M -$14M -6.39% Jul 1, 2023 Sep 30, 2023 10-Q 2024-10-23
Q2 2023 $745M $173M -$89M -34% Apr 1, 2023 Jun 30, 2023 10-Q 2024-07-19
Q1 2023 $834M $189M -$112M -37.2% Jan 1, 2023 Mar 31, 2023 10-Q 2024-04-25
Q4 2022 $946M $164M -$70M -29.9% Oct 1, 2022 Dec 31, 2022 10-K 2025-02-07
Q3 2022 $1.02B $219M -$140M -39% Jul 1, 2022 Sep 30, 2022 10-Q 2023-10-24
Q2 2022 $1.16B $262M -$137M -34.3% Apr 1, 2022 Jun 30, 2022 10-Q 2023-07-21
Q1 2022 $1.29B $301M +$11M +3.79% Jan 1, 2022 Mar 31, 2022 10-Q 2023-04-20
Q4 2021 $1.28B $234M +$28M +13.6% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-08
Q3 2021 $1.25B $359M +$260M +263% Jul 1, 2021 Sep 30, 2021 10-Q 2022-10-25
Q2 2021 $994M $399M +$388M +3527% Apr 1, 2021 Jun 30, 2021 10-Q 2022-07-21
Q1 2021 $606M $290M +$194M +202% Jan 1, 2021 Mar 31, 2021 10-Q 2022-04-21
Q4 2020 $412M $206M +$16M +8.42% Oct 1, 2020 Dec 31, 2020 10-K 2023-02-09
Q3 2020 $396M $99M -$220M -69% Jul 1, 2020 Sep 30, 2020 10-Q 2021-10-21
Q2 2020 $616M $11M -$265M -96% Apr 1, 2020 Jun 30, 2020 10-Q 2021-07-22
Q1 2020 $881M $96M -$259M -73% Jan 1, 2020 Mar 31, 2020 10-Q 2021-04-27
Q4 2019 $1.14B $190M -$39M -17% Oct 1, 2019 Dec 31, 2019 10-K 2020-02-13
Q3 2019 $1.18B $319M +$97M +43.7% Jul 1, 2019 Sep 30, 2019 10-Q 2020-10-22
Q2 2019 $1.08B $276M +$80M +40.8% Apr 1, 2019 Jun 30, 2019 10-Q 2020-07-23
Q1 2019 $1B $355M +$148M +71.5% Jan 1, 2019 Mar 31, 2019 10-Q 2020-04-22
Q4 2018 $854M $229M -$261M -53.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-13
Q3 2018 $1.12B $222M -$102M -31.5% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-13
Q2 2018 $1.22B $196M -$96M -32.9% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-13
Q1 2018 $1.31B $207M -$76M -26.9% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-13
Q4 2017 $1.39B $490M +$158M +47.6% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-15
Q3 2017 $1.23B $324M -$35M -9.75% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-15
Q2 2017 $1.27B $292M +$10M +3.55% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-15
Q1 2017 $1.26B $283M -$63M -18.2% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-15
Q4 2016 $1.32B $332M +$11M +3.43% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-22
Q3 2016 $1.31B $359M +$14M +4.06% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-22
Q2 2016 $1.29B $282M -$38M -11.9% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-22
Q1 2016 $1.33B $346M +$15M +4.53% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-22
Q4 2015 $1.32B $321M -$1M -0.31% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-23
Q3 2015 $1.32B $345M +$14M +4.23% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-23
Q2 2015 $1.3B $320M +$28M +9.59% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-23
Q1 2015 $1.28B $331M -$1M -0.3% Jan 1, 2015 Mar 31, 2015 10-K 2017-02-23
Q4 2014 $1.28B $322M +$73M +29.3% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-25
Q3 2014 $1.2B $331M -$49M -12.9% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-25
Q2 2014 $1.25B $292M -$28M -8.75% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-25
Q1 2014 $1.28B $332M +$118M +55.1% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-25
Q4 2013 $1.16B $249M Oct 1, 2013 Dec 31, 2013 10-K 2015-02-23
Q3 2013 $380M Jul 1, 2013 Sep 30, 2013 10-K 2015-02-23
Q2 2013 $320M Apr 1, 2013 Jun 30, 2013 10-K 2015-02-23
Q1 2013 $214M Jan 1, 2013 Mar 31, 2013 10-K 2015-02-23

Synchrony Financial Annual Income Tax Expense (Benefit) (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $1.05B +$388M +58.3% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-07
2023 $666M -$280M -29.6% Jan 1, 2023 Dec 31, 2023 10-K 2025-02-07
2022 $946M -$336M -26.2% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-07
2021 $1.28B +$870M +211% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-08
2020 $412M -$728M -63.9% Jan 1, 2020 Dec 31, 2020 10-K 2023-02-09
2019 $1.14B +$286M +33.5% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-10
2018 $854M -$535M -38.5% Jan 1, 2018 Dec 31, 2018 10-K 2021-02-11
2017 $1.39B +$70M +5.31% Jan 1, 2017 Dec 31, 2017 10-K 2020-02-13
2016 $1.32B +$2M +0.15% Jan 1, 2016 Dec 31, 2016 10-K 2019-02-15
2015 $1.32B +$40M +3.13% Jan 1, 2015 Dec 31, 2015 10-K 2018-02-22
2014 $1.28B +$114M +9.8% Jan 1, 2014 Dec 31, 2014 10-K 2017-02-23
2013 $1.16B -$94M -7.48% Jan 1, 2013 Dec 31, 2013 10-K 2016-02-25
2012 $1.26B Jan 1, 2012 Dec 31, 2012 10-K 2015-02-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.